KLRK1 and neoplasm: For many tumors, tumor infiltrating Klrk1/NKG2D+ CD3+ CD8+ T cells or T cells expressing chimeric Klrk1/NKG2D receptor were shown to have promising anti-tumor efficacy22, 23, 24, 25, 26, 27.